The peptide craze meets a hard question

Every few years a category of compound goes from the pages of a specialty journal to the front of a supplement shelf, and the vocabulary changes on the way. What a researcher calls "a signal worth following" becomes, by the time it reaches a checkout page, "the breakthrough your body has been waiting for." In June, Nature ran a feature that stepped back to ask the obvious question about peptides: is the boom actually backed by the science, or has the marketing simply run ahead of it?

Who was asked

The interesting thing about the piece is who it leaned on. One of the voices was Pinchas Cohen, dean of the USC Leonard Davis School of Gerontology and, as it happens, one of the people who put mitochondrial-derived peptides on the map in the first place. His lab described humanin two decades ago and MOTS-c a decade later. If anyone has a reason to talk up the category, it is him.

He didn't. The through-line of his comments was the gap between what these molecules do in a mouse or a dish and what we can honestly say they do in a person who buys a vial online. The biology is real and often elegant. The clinical evidence, for most of what's being sold, is thin or absent. Those are two different statements, and the wellness market has a habit of collapsing them into one.

Two different questions

It helps to separate the things a peptide article is usually answering at once.

The first is mechanistic: does this molecule do something in a cell? For a number of the peptides in circulation, the answer is a genuine yes. MOTS-c shifts how muscle handles energy in animal models. Copper peptides do things to skin in culture. GLP-1 receptor agonists have a mechanism so well mapped it fills textbooks. That's the part that makes the headlines exciting.

The second question is the one that matters for a human being: has this been tested, in people, at a known dose, against a placebo, with results that hold up? Here the map thins out fast. GLP-1 medicines have that kind of evidence and a regulatory approval to go with it. Most of the rest do not. A compound can sit at a confident yes on the first question and a shrug on the second, and nothing about the first obligates the second to follow.

Why the gap persists

Part of it is structure. A lot of these compounds reach people through compounding pharmacies and grey markets rather than approved products, which means no one is required to run the large, boring, expensive trials that would settle the question either way. Preclinical work is cheaper and more photogenic. So the science that gets done tends to be the science that generates a promising abstract, not the science that closes a case.

And part of it is us. A mechanism story is satisfying. It sounds like an answer. The discipline the Nature piece was quietly modeling is the willingness to hold a compound at "interesting and unproven" for as long as the evidence actually warrants, which can be years, without either dismissing it or buying the vial.

How to hold it

None of this is an argument that peptides are fake. Some of them will almost certainly earn their place, and a few already have. It's an argument for reading the claim carefully. When a peptide is described, notice which question is being answered. "Activates AMPK in muscle cells" is a mechanism. "Will improve your metabolism" is a promise, and a promise is exactly the thing the trials haven't been run to support.

The founders of a field being the ones to counsel patience is a good sign, not a discouraging one. It usually means the science is healthy enough to survive an honest accounting. The claims that last tend to be the ones their own discoverers were slow to make.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.